Connect with us

Hi, what are you looking for?

Life

FDA takes legal action against pharmaceutical company

The consent decree concerns Downing Labs (which was once called NuVision Pharmacy). The legal action claims the company manufactured and sold pharmaceutical medications, labelled as sterile, when in fact the drugs were adulterated. The adulteration relates to the manufacturing environment being assessed by the U.S. Food and Drug Administration (FDA) as “unsanitary” and not meeting the requirements of Good Manufacturing Practice (GMP).

Longstanding readers of Digital Journal may recall the case. Back in April 2013, we reported
That NuVision Pharmacy was recalling selected products, such as methylcobalamin injection, due to a lack of sterility assurance, which related to weak quality control processes. This was in the context of a number of compounding pharmacy units being cited for GMP issues. The trigger for the investigation was medical reports from clinicians who had noticed unusual reactions when certain products had been administered by injection.

The FDA issued its final report on NuVision in July 2014. This detailed various violations of the Federal Food, Drug, and Cosmetic Act (FD&C Act). A further FDA inspection in October 2015, led to the company (now rebranded as Downing Labs) initiating a further voluntary recall.

Speaking on the action, Janet Woodcock, director of the FDA’s Center for Drug Evaluation and Research stated: “Despite multiple warnings to the company, Downing Labs continued to manufacture injectable drugs under insanitary conditions, putting the health and safety of patients at risk.” On this basis Woodcock adds “the FDA pursued appropriate and aggressive action to protect the public health.”

The case against the manufacturer has been taken on behalf of FDA by the U.S. Department of Justice. The consent decree, passed by Justice Lindsay prohibits Downing Labs from manufacturing, holding or distributing drugs until they comply with the FD&C Act.

Digital Journal has run a series of investigative articles on the problems facing U.S. compounding pharmacies as the U.S. Food and Drug Administration (FDA) embarks on a series of inspections into issues of quality and sterility of medicines.

Avatar photo
Written By

Dr. Tim Sandle is Digital Journal's Editor-at-Large for science news. Tim specializes in science, technology, environmental, business, and health journalism. He is additionally a practising microbiologist; and an author. He is also interested in history, politics and current affairs.

You may also like:

Tech & Science

OK, now find someone with a clue to make any of this plausible to a broken economy.

Social Media

TMTG, which recently went public, posted a net loss of $327.6 million from January to March.

World

Rangelands like deserts, tundra and savanna are in much greater peril than previously thought - Copyright SAUDI PRESS AGENCY/AFP -Nick PerryFrom camel drivers in...

Business

Copper prices have soared to a record high, along with gold - Copyright AFP DENIS CHARLETAsian markets suffered a downturn Tuesday after racking up...